DGAP-News: EZAG to set up radiopharmaceutical production facility in ChinaEckert & Ziegler Strahlen- und Medizintechnik AG:


 

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Joint Venture/Alliance
EZAG to set up radiopharmaceutical production facility in ChinaEckert & Ziegler Strahlen- und Medizintechnik AG:

29.07.2019 / 15:43
The issuer is solely responsible for the content of this announcement.


Press Release

Berlin, 29 July 2019 - Eckert & Ziegler Strahlen- und Medizintechik AG (S-DAX, ISIN DE0005659700) and Chengdu New Radiomedicine Technology Co. Ltd. (CNRT) have finalized an agreement about setting up, in Chengdu, PR China, a new production facility for radiopharmaceuticals used in the treatment of hepatocellular carcinomas. The virtual joint venture will duplicate in China the manufacturing process of EZAG's existing German plant, thereby securing identical product quality and sufficient future capacity for the growing market of medical products based on Yttrium-90.

While CNRT will be primarily responsible for production, Eckert & Ziegler will be the exclusive global agent for sales and marketing and the point of contact for customers. "We are very happy to have found a strong strategic partner to provide Chinese cancer patients with effective and affordable radiopharmaceuticals", comments Andreas Eckert, CEO of Eckert & Ziegler. "Furthermore, the arrangement will allow pharmaceutical companies worldwide to receive their raw material in the familiar, consistent EZAG quality now from several facilities, thereby easing capacity and production planning".

The operational start of the new production line is timed to coincidence with the approval of various Y-90 based products for hepatocellular carcinomas that are currently under review by the Chinese authorities (CFDA).

About Eckert & Ziegler.
With around 800 employees Eckert & Ziegler Strahlen- und Medizintechnik AG is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. The core businesses of Eckert & Ziegler are nuclear-medical imaging, industrial radiometry and cancer therapy.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



29.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 848275

 
End of News DGAP News Service

848275  29.07.2019 

fncls.ssp?fn=show_t_gif&application_id=848275&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 117,14 127,26 139,75 137,94 138,63 168,71 178,49 168,50
EBITDA1,2 22,07 20,10 26,98 24,97 26,62 32,14 43,13 36,00
EBITDA-Marge3 18,84 15,79 19,31 18,10 19,20 19,05 24,16 21,36
EBIT1,4 12,82 12,96 18,22 16,23 17,97 23,39 32,06 25,00
EBIT-Marge5 10,94 10,18 13,04 11,77 12,96 13,86 17,96 14,84
Jahresüberschuss1 9,09 6,50 10,37 9,79 15,12 16,89 22,48 18,00
Netto-Marge6 7,76 5,11 7,42 7,10 10,91 10,01 12,59 10,68
Cashflow1,7 14,65 10,65 16,23 19,83 26,83 21,21 40,43 29,00
Ergebnis je Aktie8 1,72 1,28 2.03 1,81 2,78 3,12 4,29 3,50
Dividende8 0,60 0,60 0,60 0,66 0,80 1,20 1,70 1,70
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 152,600 Halten 807,71
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
37,22 20,02 1,877 62,39
KBV KCV KUV EV/EBITDA
6,25 19,98 4,53 17,669
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
1,70 1,70 1,11 10.06.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
12.05.2020 13.08.2020 10.11.2020 31.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,68% -3,73% -19,94% 52,75%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei DGAP abrufen

Medtech , 565970 , EUZ , XETR:EUZ